Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Valemetostat + R2 in R/R Follicular Lymphoma
NCT05683171Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2023
- Primary completion
- Sep 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of valemetostat in follicular lymphoma (FL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Incidence of Adverse Events at 1 year. Started May 2023; status: active, not recruiting.
02
Drugs
valemetostat
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT05683171.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05683171.